TRANSCATHETER TECHNOLOGIES GmbH, a Regensburg, Germany-based transcatheter heart valve company that is developing a fully repositionable device for transcatheter aortic valve implantation (TRINITY), has closed a €1.7m Series A financing round.

The round was led by Dr. Rolf Kaese from Tubaflex Beteiligungs GmbH, with participation from existing investors Technologie-Seed-Beteiligungsfonds Bayern GmbH & Co. KG and High-Tech Gründerfonds GmbH, as well as new investors Kreditanstalt für Wiederaufbau (KFW), ERP-Startfonds, Clusterfonds EFRE Bayern and other private backers.

The company intends to use the funds to technically validate the TRINITY technology, which consists of a transcatheter aortic heart valve prosthesis and implantation system that integrate an anchoring mechanism with a delivery catheter to enable the valve prosthesis to be precisely positioned.

In conjunction with the funding, Dr. Kaese from Tubaflex and Dirk Dreyer, Director Globals Sales & Marketing and member of the Executive Board of Straub Medical AG, Switzerland, will join Transcatheter Technologies’ advisory board.

Incorporated in 2009, the company is led by CEO and cardiac surgeon Dr. Wolfgang Goetz.



Join the discussion